Open AccessEfficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
Author(s) -
Dongxu Wang,
Yang Xu,
Jianzhen Lin,
Yi Bai,
Junyu Long,
Xiaobo Yang,
Samuel Seery,
Haitao Zhao
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i30.4465
Subject(s) - lenvatinib , medicine , hepatocellular carcinoma , hazard ratio , sorafenib , oncology , adverse effect , liver cancer , population , gastroenterology , retrospective cohort study , confidence interval , environmental health
Lenvatinib has become an indispensable part of treatment regimens for patients with advanced hepatocellular carcinoma (aHCC). Several recent real-world studies appear to have confirmed this; however, there are etiological differences. This necessitates further real-world studies of lenvatinib across diverse populations, such as in China.